BioGenes Reports Strong Growth of HCP Assay Development Business
News Feb 28, 2013
BioGenes GmbH announced a strong increase in sales volume in 2012, the year of the company’s 20th anniversary, due to a high demand of specific antibodies and ELISA assays used in drug development processes. In particular, the HCP assay development business showed a remarkable growth increasing by 36% over 2011.
BioGenes is a recognized partner of pharmaceutical companies all over the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.
“Our long-term strategy to focus on HCP assay development pays off and we expect the growth to continue at a similar pace in the months ahead,” said Dagmar Schwertner-Knoll, Marketing Director of BioGenes. “The next milestone is the development of pre-optimized HCP assay kits for more reliable host cell protein detection.”
Comments | 0 ADD COMMENT
7th International Conference on Tissue Science and Regenerative Medicine
Oct 02 - Oct 04, 2017
Removing Old Cells Could Prevent Joint Degeneration
News Apr 26, 2017